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Background: Type 2 diabetes mellitus (DM2) is a disease with high prevalence and significant impact in terms of
mortality and morbidity. The increased prevalence of the disease requires the implementation of new strategies to
promote patient self-management. The Spanish Diabetes Self-Management Program (SDSMP) has proven to be
effective in other settings. The objective of this study is to assess its effectiveness in terms of care for DM2 patients
in primary care settings within the Basque Health Service – Osakidetza (Spain).
Method/Design: This is a randomised clinical trial in which patients diagnosed with DM2, 18–79 years of age, from
four health regions within the Basque Health Service will be randomised into two groups: an intervention group,
who will follow the SDSMP, and a control group, who will receive usual care in accordance with the clinical
guidelines for DM2 and existing regulations in our region. The intervention consists of 2,5 hour-group sessions once
a week for six weeks. The sessions cover target setting and problem solving techniques, promotion of physical
exercise, basic knowledge of nutrition, proper use of medication, effective communication with relatives and health
professionals, and basic knowledge about DM2 and its complications. This content is complemented by
educational material: books, leaflets and CDs. The primary outcome measure will be the change in glycated
haemoglobin (HbA1c), and secondary outcome measures will include changes in levels of physical activity and
intake of fruit and vegetables, cardiovascular risk, quality of life, self-efficacy, number of consultations and drug
prescriptions. The results will be analysed 6, 12 and 24 months after the intervention.
Discussion: If the intervention were to be effective, the programme should be spread to the entire diabetic
population in the Basque Country and it could also be applied for other diseases.
Trial registration: ClinicalTrials.gov identifier NCT01642394
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Managing patients with chronic health problems repre-
sents a challenge for health services. According to the
2007 Basque Health Survey, chronic diseases are in-
creasingly prevalent in our setting, currently, 83.5% of
women and 86.1% of men aged over 65 years having
some type of chronic condition [1]. In the health sys-
tem, 80% of primary care consultations are related to
chronic diseases, as 60% of hospital admissions and
70% of health expenditure [2].
In particular, the incidence of type 2 diabetes mellitus
(DM2) has increased in our region in recent years. In-
deed, it is predicted that prevalence of DM2 may reach
up to 12% in the population over 30 years of age [3].
Mortality and morbidity in DM2 patients are known to
be much higher than those in the general population;
specifically, in diabetic patients, the mortality rate ranges
from 13 to 30 deaths per 100,000 people per year, and
75% of these deaths are due to heart disease [3]. Further,
it has been estimated that diabetes accounts for as much
as 6.3 to 7.4% of health expenditure in our health sys-
tem, while 42% of people with diabetes in our region are
obese, 79.6% have high blood pressure and 22% have
diabetic macroangiopathy [4]. According to the latest
internal assessment data, there is room for im-
provement in diabetes control in our setting. Well-
controlled diabetic patients, that is, those with
HbA1c levels below 7%, represent just 44% of the
overall diabetic population, and blood pressure is
under 140/90 in only 25% of patients (unpublished
data from internal assessments in the Basque Health
Service, Osakidetza).
Health systems need to provide more efficient and co-
ordinated care to patients with chronic conditions and
this should be focused on decreasing rates of deterior-
ation and improving the quality of life of patients and
their families/caregivers. In relation to this, primary care
has an essential role [2]. As in other developed coun-
tries, the Spanish Health System is outdated, and a new
organisational model is needed to respond to the chal-
lenge of providing care to chronic patients [5]. Though
several models have been proposed, the Chronic Care
Model and the Kaiser Permanente model are among the
most used and studied [2].
In both models, a key role is given to self-management
and educational programmes, implying patient involve-
ment in the management of their own condition. Among
such programmes, the most widely used and studied
structured approach is that of the Chronic Disease Self-
Management Program (CDSMP) developed at Stanford
University. The CDSMP is based on the self-efficacy the-
ory of Albert Bandura [6], a social cognitive theory,
which establishes two key factors in the achievement of
successful behavioural change: confidence (self-efficacy)in one’s ability to perform a task, and the expectation of
achieving a specific target (outcome expectation).
Despite the many systematic reviews published on the
efficacy of different self-management education models
[7-9], observed outcomes are heterogeneous due to the
variable duration of study periods, types of interventions
and target populations. What is more, programmes have
not been assessed over the long-term.
In our setting, the pilot studies using this method have
been promising, but have not yet been rigorously and
prospectively evaluated compared to usual care [10]. A
very recent trial, conducted in a different healthcare
context, in male war veterans in the United States, has
demonstrated that an educational intervention led by pa-
tients themselves is more effective for controlling gly-
caemic levels than one run by nurses [11]. Another
recent study of a patient-led intervention, in primary
care in Ireland, peer support found that the intervention
was not effective in decreasing HbA1c levels in DM2 pa-
tients; however, the programme used was designed by
the research team and placed more emphasis on social
support than educational aspects [12], which is a differ-
ent approach to that of the Spanish Diabetes Self-
Management Program (SDSMP).
The Health Department of the Basque Country Gov-
ernment is promoting a new strategy for chronic patient
care based on the Chronic Care Model (http://
cronicidad.euskadi.net). Two of the cornerstones of this
model are self-care promotion and population education.
In this context, the “Active Patient” programme, based
on the SDSMP which shares core elements with the
CDSMP, has been proposed as a useful instrument for
promoting self-care in patients with DM2. In order to
assess the effectiveness of this programme, compared to
usual care for DM2 patients in the Basque Health Ser-
vice, we decided to conduct a clinical trial. The present




To assess the effect of the SDSMP on glycaemic control
in DM2 patients compared to usual care provided to this
type of patient in primary care in the Basque Health
System.
Secondary objectives
 To assess any changes in
o level of cardiovascular risk




Gamboa Moreno et al. BMC Public Health 2013, 13:521 Page 3 of 8
http://www.biomedcentral.com/1471-2458/13/521 To evaluate the use of health resources by diabetic
patients
 To assess the impact of the SDSMP on drug
prescription and associated costs
 To describe the feasibility of implementing SDSMP
within primary care in the Basque Health System.
Hypothesis
An educational intervention for DM2 patients, based on
the SDSMP, will be conducted by two leaders. At least
one of them will be a chronic patient and have previ-
ously received specific training. This intervention will
improve metabolic control, with a decrease of 0.5% or
more in HbA1c levels [13], in comparison to usual
health education.
Design
A randomised clinical trial will be carried out in four
health regions of the Basque Health Service (Araba,
Gipuzkoa, Ezkerraldea-Enkarterri and the Bidasoa Inte-
grated Health Organisation) involving a total of 556
DM2 patients between 18 and 79 years old, recruited
proactively, as described in the section on the recruit-
ment process below. Patients will be randomly assigned
to intervention and control groups, and will be followed
up over two years. Measurements will be taken at four
time points: baseline, and 6, 12 and 24 months after the
intervention. The research protocol has been approved
by the Basque Country Clinical Research Ethics Com-
mittee (Ref. no.: 11/2010).
Study subjects
Eligibility criteria
Patients must be 18 years old or above and have DM2,
must be from one of four aforementioned health regions
within the Basque Country, and must agree to partici-
pate in the Active Patient programme: “Paciente Activo-
Paziente Bizia”.
Exclusion criteria
We will exclude individuals over 80 years of age, those
with mental disorders associated with a loss of a sense
of reality (schizophrenia, bipolar disorder, Alzheimer´s
disease, psychosis or dementia) and those with any asso-
ciated morbidity that might impede their participation in
the course, such as is the case for chronic patients re-
quiring home care.
Recruitment process
Eligible patients will be recruited in several ways:
through advertisements for volunteers in the local
media; by sending letters addressed to patients diag-
nosed with DM2, based on data from the Osabide elec-
tronic health record; and by their assigned healthprofessionals (general practitioners and nurses) directly
inviting them to participate.
Patients will be informed about the objectives of the
study, and those willing to participate will be randomly
assigned to intervention or control groups, after giving
written informed consent. The baseline measurements
will be taken before the randomisation process
(Figure 1).
Withdrawal from the study
Participants will be able to withdraw from the study at
any point if they wish. Those in the intervention group
must participate in a minimum of four educational ses-
sions; else, they will be considered as dropouts. All those
randomised will, nevertheless, be included for the statis-
tical analysis (i.e., data will be analysed on an intention-
to-treat basis).
Randomisation
Randomisation will be performed centrally by staff other
than those of the research team, using a computer-
generated random number sequence and after taking the
baseline measurements.
Standardization of the intervention
Intervention group
The complete intervention consists of group sessions (8
to 15 people) lasting 2.5 hours, once a week for six
weeks. These sessions are structured with the aim of en-
abling participants to acquire knowledge and skills re-
lated to the disease and its management, placing a
strong emphasis on proactive tools to achieve healthier
lifestyles (in terms of diet, physical exercise, manage-
ment of emotions, and correct use of medication, among
others).
During the sessions, patients will be taught how to set
realistic achievable targets, cope with problems related
to their disease, communicate more effectively with rela-
tives and health professionals sharing their feelings, and,
overall, have an active attitude towards managing their
disease and towards more healthy lifestyles. The sessions
are supported by educational materials: books, leaflets
and CDs.
Each group will be supervised by two leaders, who
have previously been trained in the SDSMP. This train-
ing consists of two parts: the first, 24-hours of theoret-
ical training, given by two Master Trainers certified by
Stanford University; and, the second, practice, which in-
volves trainees running a workshop with patients. Hav-
ing completed these two components of the training,
they can be certified as leaders. At least one of the two
leaders should be a chronic patient him/herself or care-
giver for a chronic patient. Leaders who are themselves
chronic patients, or have close personal experience of a
2 nd assessment: 6 months 
after the end of the 
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Patients with type 2 diabetes 
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Figure 1 Flowdiagram for the study.
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suggest more appropriate and realistic options than
health professionals. The other leader, who is a doctor or
nurse, should introduce himself to patients on the
courses as an SDSMP programme leader, rather than as
a health professional, as this strengthens the idea of peer
education.
Control group
Patients assigned to the control group will receive usual
care for secondary prevention of DM2 in accordance
with the Osakidetza primary care protocols, which are
based on clinical practice guidelines [14].
Outcome variables
Baseline measurements will be taken prior to random-
isation. As noted above, the clinical data will be col-
lected at each health centre by collaborating health
professionals, previously trained by the research team.
Some instruments to be used are for self-completion by
patients, while others are questionnaires for use by inter-
viewers previously trained by the research team.
Blood samples will be collected by staff at the patients’
assigned health centres, and the analysis will be
performed at the reference laboratories of the four par-
ticipating health regions.
Primary outcome measure
Change in glycosylated haemoglobin (HbA1C) levels
Secondary outcome measures
Changes in the following:
 Body weight, height and BMI measured in standard
conditions
 Systolic and diastolic blood pressure (SBP and
DBP) measured by a validated automated
sphygmomanometer following the
recommendations in the 2007 Osakidetza clinical
practice guidelines [14]
 Total and HDL cholesterol levels
 REGICOR cardiovascular risk scores [15]
 Quality of life assessed by the Spanish version of the
ADDQoL-19 [16]
 Self-efficacy assessed using the Diabetes Self-efficacy
Scale from Stanford University, and the level of
physical activity assessed by the 7-day Physical
Activity Recall (PAR) [17] questionnaire
 Mediterranean-Dietary Quality Index (PREDIMED
Study)
 Medication taken for DM and associated risk factors
(hypoglycaemic, antiplatelet, antihypertensive and
lipid-lowering medication)
 Daily expenditure on medication Use of health services (number of visits to the
doctor or nurse, admissions due to diabetes-related
metabolic decompensation)
Independent variables
Age; sex; number of years since diagnosis of diabetes; his-
tory of diabetic microvascular disease: retinopathy, ne-
phropathy or neuropathy; history of diabetic macrovascular
disease: heart disease, peripheral arterial disease or cerebro-
vascular accident; treatment with anti-hyperglycaemic
drugs: oral hypoglycaemic agents or insulin; and pre-
ventive cardiovascular medication: antiplatelet, antihy-
pertensive and lipid-lowering drugs.
Variables related to the group intervention
Leader conducting the sessions
Variables related to the implementation
Percentage of the overall diabetic population invited
who agree to participate in the programme; percentage
of patients who agree to participate that then complete
the programme; number of patients who go on to be-
come trainers for the “Active Patient” programme; re-
sults of the satisfaction survey; number and percentage
of health professionals involved at each centre who con-
duct the regular check-ups for diabetes patients partici-
pating in the research; and number and percentage of
professionals who become trainers in the Active Patient
programme.
Both the intervention and control groups will have
four sets of measurements taken: prior to the interven-
tion and 6, 12 and 24 months after the intervention.
Data management
The research team will run a training session for collab-
orators in the health centres, to ensure consistency in
the data collection. In addition, printed and electronic
support material will be available in each participating
centre.
The researchers at each centre will collect the data
using a form designed for this purpose. These data will
be then stored in a password-protected Access database
using double-data entry designed for the purpose. Simi-
larly, the interviewers will enter the data into an Access
database designed for the purpose. A report on the qual-
ity of data obtained will be produced once a month.
Sample size
Based on the results of a pilot study with 171 patients,
we found a standard deviation (SD) of 1.2% in HbA1c
and, given that that the mean SD in literature is around
2%, we used an SD of 1.5% to calculate the sample size.
Considering an intra-class correlation of 0.05 [18] and
an average of 10 participants per group, we calculated
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a clinically relevant difference of 0.5% in HbA1c levels at
12 months, with 80% power, with p-value of 0.05 and as-
suming a dropout rate of 15%.
Data analysis
The categorical variables will be presented as frequencies
and percentages (%) while the continuous variables will
be reported as means and SDs. Patients in the interven-
tion and control groups will be compared on an
intention-to-treat basis. To assess the intervention effect,
we will compare changes observed in each of the groups
using Chi-square tests for categorical variables, and Stu-
dent’s t-tests for continuous variables in the two inde-
pendent groups, for each of the repeated measurements.
To adjust variables that may confound or moderate the
effect of the intervention, we will perform stratified ana-
lysis and multivariate regression analysis. Multilevel ana-
lysis, i.e., generalized mixed-effects models, will be used
to estimate baseline and multivariate-adjusted between-
group mean differences, adjusted odds ratios (AORs),
and 95% confidence intervals (CIs) at the patient level,
taking into account the clustered structure of data for
patients for whom the intervention has been led by dif-
ferent individuals.
Longitudinal generalized mixed models will be used to
analyse the overall trend in changes in the outcome
measures taking into account the repeated measure-
ments for each patient and also the clustered structure
of data. These models will be linear for continuous vari-
ables, and logistic for categorical variables. Time will be
considered in these models as a continuous variable,
based on linear, quadratic or logarithmic functions, or as
a categorical variable, with several correlated measure-
ments for each individual. The least restrictive option
with the best fit to the data will be chosen. The interven-
tion, the time of measurement and intervention-time
interaction will be included as fixed effects in the
models. Patients and leaders will be included as random
effects on the intercept and on the time slope. These
models will be extended to include variables that may
confound or modify the effect of the intervention, this
being guided by the stratified analysis. At this stage, re-
sults will be presented as coefficients with their respect-
ive 95% confidence intervals. The analysis will be
performed using SAS v. 9.2, SPSS v. 19 and R.
Discussion
The objective of this clinical trial is to assess the effect-
iveness of the SDSMP in contrast to usual care for DM2
patients within primary care in the Basque Country. This
intervention, while providing knowledge concerning the
disease and its management, is different from the usual
health educational models in the sense that it involvespeer group education and puts considerable emphasis
on reinforcing attitudes and skills that enhance proactiv-
ity, such as target setting, problem solving, positive
thinking, communication techniques, dealing with feel-
ings, and proper use of prescribed treatments. This
should empower patients to more actively manage their
lifestyles, changing towards healthier habits and achiev-
ing improvements in diet, physical exercise, correct use
of medications, and relationships with their healthcare
provider, as well as with their relatives and friends.
Existing self-care education programmes [7] are based
on a range of different methods and measure different
variables and, further, they have not been assessed by
prospective and controlled studies in our health system.
On the other hand, these types of intervention are often
mentioned in debates about the changes required in
health systems to face the current demographic situ-
ation. It is, therefore, necessary to provide good quality
evidence to guide the selection of appropriate interven-
tions by undertaking controlled randomised clinical tri-
als assessing their effectiveness [19].
In our health setting, the feasibility of implementing
such a programme would rely on it being integrated into
the everyday practice of health professionals and on
gaining support and acceptance among patients as well
as leaders. If this research in our setting yields the
hoped-for results, this would give us a tool for improv-
ing the care provided to patients with diabetes and other
chronic diseases. The courses could be adapted to differ-
ent disorders and thereby improve self-care among a
wider population, leading to more self-efficacy, greater
quality of life, better clinical outcomes and proper use of
healthcare services, and therefore a more efficient use of
resources.Limitations of the study
The selection criteria may limit the external validity of
the intervention as otherwise eligible patients with ad-
vanced age and comorbidity will be excluded. Further, it
is necessary to recognise that participation in any train-
ing activity implies a degree of willingness on the part of
the patient. We consider that this predisposition should
not represent a bias in the study, given that performing
the randomisation after patients have shown willing to
participate should ensure comparability between groups.
On the other hand, working patients, in particular, may
have constraints on attending group sessions due to
other commitments. To limit the impact of this prob-
lem, the courses will be offered at as wide a range of
times as possible. The clinical workload of the health
professionals involved in the research may, however,
impose restrictions on the timetable of the training
sessions.
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